Lundbeck adds regulatory unit to its research operations

Danish pharma company Lundbeck has set up a new unit within its research operations to focus on regulatory product support, patient safety and quality assurance of clinical research.

It will be led by Jens Peter Balling, who has been appointed vice president of regulatory affairs, pharmacovigilance and clinical quality assurance within the company's R&D operations.

Balling has been with Lundbeck since 2006, when he joined as divisional director of global pharmacovigilance, and previously worked for Novo Nordisk and Nycomed.

He will be joined in the new unit by Iman Barilero, also newly appointed as vice president of regulatory development strategy and policy and who has a liaison role with regulatory authorities.

Anders Gersel Pedersen, Lundbeck's executive vice president of research and development, said: "The appointments of Jens Peter Balling and Iman Barilero reflect our efforts to build a strong and competent research and development organisation that enables us to continue to deliver results as we invest in the future. The regulatory and safety areas are an increasingly important prerequisite for this.

“The creation of one new unit and the increased focus on the other gives us a strong position in these areas.”